SINUS SURGERY AND STEROID USE IN ADULTS

In SINUS trials, 63% of patients
had prior surgery^1,2

83^%

REDUCTION IN THE
NEED
FOR SINUS
SURGERY

vs placebo through
Week 52
(HR: 0.17
[95% CI: 0.07, 0.46])¹

74^%

REDUCTION IN THE
NEED FOR SYSTEMIC
STEROID USE

vs placebo through
Week 52
(HR: 0.26
[95% CI: 0.18, 0.38])¹

There was a 76% reduction in the need for surgery and/or systemic steroids vs placebo through Week 52 (HR: 0.24 [95% Cl: 0.17, 0.35]).^1,a,b

^aIndividually, systemic steroid use reduction and need for sinus surgery were not multiplicity-adjusted endpoints.^1,2

^bIn SINUS-24 and SINUS-52, DUPIXENT 300 mg Q2W + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).¹

CRSwNP, chronic rhinosinusitis with nasal polyps; HR, hazard ratio; INCS, intranasal corticosteroids; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.¹